Literature DB >> 22410678

Prostate cancer: modeling the outcomes of prostate cancer screening.

Stacy Loeb, Sigrid Carlsson, R Scott Braithwaite.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22410678     DOI： 10.1038/nrurol.2012.34

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  8 in total

1.  The Finnish trial of prostate cancer screening: where are we now?

Authors:  P Finne; U H Stenman; L Määttänen; T Mäkinen; T L J Tammela; P Martikainen; M Ruutu; M Ala-Opas; J Aro; P J Karhunen; J Lahtela; P Rissanen; H Juusela; M Hakama; A Auvinen
Journal:  BJU Int       Date:  2003-12       Impact factor: 5.588

2.  ERSPC and PLCO prostate cancer screening studies: what are the differences?

Authors:  Fritz H Schröder; Monique J Roobol
Journal:  Eur Urol       Date:  2010-03-26       Impact factor: 20.096

3.  Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial.

Authors:  Paul F Pinsky; Gerald L Andriole; Barnett S Kramer; Richard B Hayes; Philip C Prorok; John K Gohagan
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

4.  The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen.

Authors:  Grace Hui-Min Wu; Anssi Auvinen; Amy Ming-Fang Yen; Matti Hakama; Teuvo L Tammela; Ulf-Håkan Stenman; Paula Kujala; Mirja Ruutu; Hsiu-Hsi Chen
Journal:  Eur Urol       Date:  2012-01-14       Impact factor: 20.096

5.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.

Authors:  Jonas Hugosson; Sigrid Carlsson; Gunnar Aus; Svante Bergdahl; Ali Khatami; Pär Lodding; Carl-Gustaf Pihl; Johan Stranne; Erik Holmberg; Hans Lilja
Journal:  Lancet Oncol       Date:  2010-07-02       Impact factor: 41.316

6.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Claudine Isaacs; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Lawrence R Ragard; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Ann W Hsing; Grant Izmirlian; Paul F Pinsky; Barnett S Kramer; Anthony B Miller; John K Gohagan; Philip C Prorok
Journal:  J Natl Cancer Inst       Date:  2012-01-06       Impact factor: 13.506

7.  Screening and prostate-cancer mortality in a randomized European study.

Authors:  Fritz H Schröder; Jonas Hugosson; Monique J Roobol; Teuvo L J Tammela; Stefano Ciatto; Vera Nelen; Maciej Kwiatkowski; Marcos Lujan; Hans Lilja; Marco Zappa; Louis J Denis; Franz Recker; Antonio Berenguer; Liisa Määttänen; Chris H Bangma; Gunnar Aus; Arnauld Villers; Xavier Rebillard; Theodorus van der Kwast; Bert G Blijenberg; Sue M Moss; Harry J de Koning; Anssi Auvinen
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

8.  The payoff time: a flexible framework to help clinicians decide when patients with comorbid disease are not likely to benefit from practice guidelines.

Authors:  R Scott Braithwaite; David Fiellin; Amy C Justice
Journal:  Med Care       Date:  2009-06       Impact factor: 2.983
  8 in total
  2 in total

1.  Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Authors:  Stacy Loeb; Qinlian Zhou; Uwe Siebert; Ursula Rochau; Beate Jahn; Nikolai Mühlberger; H Ballentine Carter; Herbert Lepor; R Scott Braithwaite
Journal:  Eur Urol       Date:  2017-08-23       Impact factor: 20.096

2.  Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.

Authors:  Roman Gulati; John L Gore; Ruth Etzioni
Journal:  Ann Intern Med       Date:  2013-02-05       Impact factor: 25.391
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.